Articles

Find an Article

Filter articles

Applied Filters

Showing 91 to 100 of 264 results

IP Life Sciences Exchange: a preview

Germany07-11-2016

The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.

Brexit: a fresh start for SPCs?

EU, UK20-10-2016Paul England and Matthew Royle

The UK’s vote to leave the EU may allow Britain to replace the SPC regulation—an often-criticised piece of law—and take a fresh approach to the system governing these rights, say Paul England and Matthew Royle of Taylor Wessing.

IP service providers: a more cost-effective solution post M&A?

International18-10-2016Melissa Pillote

With specialist IP providers offering post-M&A services at lower cost than traditional law firms, have clients been overspending in the past? Melissa Pillote on behalf of Dennemeyer reports.

Russian patent law: Natural selection

Russia17-10-2016Valery Djermakian

There is some debate among Russian legal professionals about whether “selection inventions” are considered patentable, but the answer seems clear, says Valery Djermakian of Gorodissky & Partners.

Technology transfer: A smart way of working

International14-10-2016Montserrat González-Álvarez

‘Technological intelligence’ is very important for extracting maximum value from technology transfer deals, and life sciences companies should use it to their advantage, says Montserrat González-Álvarez of Leyva, Montenegro, Trigueros Abogados.

Pay-for-delay: Play by the rules

EU14-10-2016Bernd Allekotte and Franz Zimmer

The EU General Court’s decision in September to fine Lundbeck nearly €150 million over several pay-for-delay deals will encourage the European Commission to take further action against similar agreements, say Bernd Allekotte and Franz Zimmer of Grünecker.

The post-Brexit picture for orphan drugs

EU, UK13-10-2016Kei Enomoto

The UK government must ensure that the vital market for orphan drugs will continue to prosper following Brexit, says Kei Enomoto of Maucher Jenkins.

Working together wisely

International12-10-2016Oliver Laing and Tony Proctor

In a world where research projects are increasingly carried out by several parties in different countries, companies should consider a number of IP-related issues before embarking on multiterritorial collaborations, say Oliver Laing and Tony Proctor of Potter Clarkson.

Francis Crick Institute: a new centre of excellence

UK11-10-2016

In September 2016, the Francis Crick Institute opened the doors to its multimillion-pound new home in London. With a wide range of research being undertaken, LSIPR examines the role of IP and the associated challenges for the organisation.

A woolly debate: the rights and wrongs of cloning

EU, UK10-10-2016

Dolly the Sheep, which would have been 20 this year, raised the possibility of cloning and forced politicians and IP practitioners to address the ethics of the process, with differing results in the US and the UK, as LSIPR reports.

Showing 91 to 100 of 264 results

LSIPR